DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML
Open Access
- 30 August 2014
- journal article
- research article
- Published by Springer Nature in Genome Biology
- Vol. 15 (7) , 1-20
Abstract
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors, 5-azacytidine and 5-aza-2′-deoxycytidine (decitabine), benefit some MDS/AML patients. However, the role of DNA methyltransferase inhibitor-induced DNA hypomethylation in regulation of gene expression in AML is unclear. We compared the effects of 5-azacytidine on DNA methylation and gene expression using whole-genome single-nucleotide bisulfite-sequencing and RNA-sequencing in OCI-AML3 cells. For data analysis, we used an approach recently developed for discovery of differential patterns of DNA methylation associated with changes in gene expression, that is tailored to single-nucleotide bisulfite-sequencing data (Washington University Interpolated Methylation Signatures). Using this approach, we find that a subset of genes upregulated by 5-azacytidine are characterized by 5-azacytidine-induced signature methylation loss flanking the transcription start site. Many of these genes show increased methylation and decreased expression in OCI-AML3 cells compared to normal hematopoietic stem and progenitor cells. Moreover, these genes are preferentially upregulated by decitabine in human primary AML blasts, and control cell proliferation, death, and development. Our approach identifies a set of genes whose methylation and silencing in AML is reversed by DNA methyltransferase inhibitors. These genes are good candidates for direct regulation by DNA methyltransferase inhibitors, and their reactivation by DNA methyltransferase inhibitors may contribute to therapeutic activity.Keywords
This publication has 51 references indexed in Scilit:
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor CellsCancer Cell, 2012
- Directional DNA Methylation Changes and Complex Intermediate States Accompany Lineage Specificity in the Adult Hematopoietic CompartmentMolecular Cell, 2011
- Increased methylation variation in epigenetic domains across cancer typesNature Genetics, 2011
- Epigenetic modifications as therapeutic targetsNature Biotechnology, 2010
- Human DNA methylomes at base resolution show widespread epigenomic differencesNature, 2009
- Targeted and genome-scale strategies reveal gene-body methylation signatures in human cellsNature Biotechnology, 2009
- The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shoresNature Genetics, 2009
- Chromatin Signatures in Multipotent Human Hematopoietic Stem Cells Indicate the Fate of Bivalent Genes during DifferentiationCell Stem Cell, 2009
- Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genomeNature Genetics, 2007
- Applied bioinformatics for the identification of regulatory elementsNature Reviews Genetics, 2004